Nimesulide prig.suspenzii granules for oral 100mg 2r pack. 30 pc

Description

Composition
Active substance:
Nimesulide – 0.100 g (100% substance) ;.
Excipients:
Sucrose (sugar) – 1,805 g, macrogol glycyl-rilgidroksistearat – 0,008 g, citric acid – 0.03 g maltodextrin – 0.015 g Orange flavoring – 0,04 g
Description:
Granules circular and irregular shape from light yellow to yellow with inclusions of yellow color, with orange smell. Presence of the powder from light yellow to yellow in color with inclusions of yellow.
Product form:
Packaging – 30 bags.
Contraindications
– hypersensitivity to nimesulide or other components of the formulation; – hyperergic reaction history (bronchoconstriction, rhinitis, urticaria), associated with the use of aspirin or other NSAIDs, including nimesulide; – full or partial combination of asthma, recurrent nasal polyposis or paranasal sinuses intolerant of aspirin and other NSAIDs (including history); – hepatotoxic reactions to nimesulide history; – simultaneous use with other drugs with potential hepatotoxicity (e.g., other NSAIDs); – chronic inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) in acute phase; – the period after coronary artery bypass surgery; – at cold febrile syndrome and acute respiratory viral infections; – suspected acute surgical pathology; – gastric ulcer or duodenal ulcer in the acute phase; erosive and ulcerative lesions of the gastrointestinal tract; perforation or gastrointestinal bleeding in history; – history of cerebrovascular bleeding or other diseases accompanying the increased bleeding; – severe blood coagulation disorders; – severe heart failure; – severe renal insufficiency (creatinine clearance
Carefully
Arterial hypertension, diabetes, compensated heart failure, ischemic heart disease, cerebrovascular disease, dyslipidemia / hyperlipidemia, peripheral arterial disease, hemorrhagic diathesis, smoking and creatinine clearance of 30 to 60 ml / min. Ulcerative lesions of the gastrointestinal tract in history; infection caused by infection with Helicobacter pylori history; elderly age; long previous use of NSAIDs; severe somatic disease. The simultaneous use of the following drugs: anticoagulant (e.g., warfarin), antiplatelet agents (e.g., aspirin, clopidogrel), oral corticosteroids (e.g., prednisone), selective serotonin reuptake inhibitor (such as citalopram, fluoxetine, paroxetine, sertraline).
Dosage
100 mg
Indications
– acute pain (pain in the back, waist, pain in the musculoskeletal system, including contusions, sprains, and dislocations of the joints, tendinitis, bursitis, toothache); – symptomatic treatment of osteoarthritis (osteoarthritis), pain syndrome; – Primary algomenorrhea.
The drug is intended for the symptomatic therapy reduce pain and inflammation at the time of use; Nimesulide is recommended for therapy as a second-line drug.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug.
Pharmacodynamics:
Nonsteroidal antiinflammatory drugs (NSAIDs), anti-inflammatory, analgesic, antipyretic, and antiplatelet effect. Unlike other NSAID selectively inhibits cyclooxygenase-2, inhibits the synthesis of prostaglandins in inflammation; has a less pronounced inhibitory effects on cyclooxygenase-1 (rarely causes side effects associated with inhibition of prostaglandin synthesis in healthy tissues).
Pharmacokinetics:
Suction. Absorption ingestion – high (meal lowers the absorption rate without affecting its degree). The time to reach maximum concentration (TSmax) – 1.5 – 2.5 hours Connection to plasma proteins -. 95%, from 2% erythrocytes with lipoproteins – 1%, with alpha 1-acidic glycoprotein – 1%. Changing the dose has no effect on the binding. Distribution. The maximum concentration of – 3.5 – 6.5 mg / l. The volume of distribution – 0.19 – 0.35 L / kg. It penetrates the tissues of female reproductive organs, where after a single dose, its concentration is about 40% of the concentration in plasma. It penetrates the acidic environment of the inflammatory focus (40%), synovial fluid (43%). Easily penetrates the blood-tissue barriers. Metabolism. It is metabolized in the liver tissue monooxygenase. The major metabolite – 4-hydroxynimesulide (25%), has a similar pharmacological activity, but due to the reduction in size of molecules capable of rapidly diffusing hydrophobic channel cyclooxygenase-2 binding to the active site of a methyl group. 4-hydroxynimesulide is a water soluble compound, for which removal is not required and glutathione conjugation reaction phase II metabolism (sulfation, glucuronidation, etc.). Withdrawal. The half life of nimesulide – 1.56 – 4.95 h, 4-hydroxy-nimesulide – 2.89 -. 4.78 hours 4-hydroxynimesulide excreted by the kidneys (65%) and in bile (35%) undergoes enterohepatic recycling.
Pregnancy and breast-feeding
Use of the drug can impair female fertility and is not recommended for women planning pregnancy. Contraindicated in be- belt. At the time of treatment should stop breastfeeding.
Dosing and Administration
Inside. The contents of the sachet are dissolved in about 100 ml of water at room temperature (white slurry formed with yellowish-gray tint). The prepared solution can not be stored. Nimesulide drug is used only for the treatment of patients older than 12 years. Adults and children over 12 years: 1 sachet twice a day after meals. Elderly patients: the treatment of elderly patients need correction daily dose determined by the physician based on the possibility of interaction with other drugs. Patients with renal impairment: Patients with renal insufficiency mild and moderate severity (creatinine clearance 30 – 60 ml / min) a dose adjustment is required, whereas patients with severe renal failure (creatinine clearance
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist